{
    "clinical_study": {
        "@rank": "121175", 
        "arm_group": [
            {
                "arm_group_label": "Faldaprevir QD high dose", 
                "arm_group_type": "Experimental", 
                "description": "capsules, oral administration with 240 ml water, fed conditions"
            }, 
            {
                "arm_group_label": "Faldaprevir QD low dose", 
                "arm_group_type": "Experimental", 
                "description": "tablets/capsules, oral administration with 240 ml water, fed conditions"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "capsules, oral administration with 240 ml water, fed conditions"
            }, 
            {
                "arm_group_label": "Ciprofloxacin", 
                "arm_group_type": "Active Comparator", 
                "description": "tablets, oral administration with 240 ml water, fed conditions"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate the potential of Faldaprevir to induce skin phototoxicity, immediate or\n      delayed type, to UV light and visible light in healthy male and female subjects.  To\n      investigate the degree, wavelength dependency, severity, pigmentation and morphology of the\n      phototoxic effects.  The persistence of the phototoxic susceptibility will be explored\n      following cessation of study medication.  Within a sunscreen sub-study, the efficacy of\n      commercially available high factor sunscreen will also be assessed in terms of its potential\n      to prevent any phototoxic skin responses seen.  The safety and tolerability of Faldaprevir\n      will also be assessed."
        }, 
        "brief_title": "A Study to Investigate the Phototoxic Potential of Faldaprevir", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Health male and female subjects with no clinically significant abnormality (according\n             to the Investigator's assessment) identified from a complete medical history,\n             physical examination, whole body skin assessment, 12-lead ECG, vital signs and\n             clinical laboratory tests.  In particular, there should be no evidence of abnormal\n             photosensitivity\n\n          -  Sun-reactive skin phototype I, II, or III\n\n        Exclusion criteria:\n\n        - Any relevant deviation from healthy conditions."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02114671", 
            "org_study_id": "1241.42", 
            "secondary_id": "2013-000767-88"
        }, 
        "intervention": [
            {
                "arm_group_label": "Faldaprevir QD high dose", 
                "description": "capsules, oral", 
                "intervention_name": "Faldaprevir high dose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "capsule, oral", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ciprofloxacin", 
                "description": "tablets, oral", 
                "intervention_name": "Ciprofloxacin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Faldaprevir QD low dose", 
                "description": "capsules, oral", 
                "intervention_name": "Faldaprevir low dose", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ciprofloxacin"
        }, 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Edinburgh", 
                    "country": "United Kingdom"
                }, 
                "name": "1241.42.44001 Boehringer Ingelheim Investigational Site"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomised, Assessor-blind, Placebo and Active Controlled, Parallel Group Study to Assess the Phototoxic Potential of Faldaprevir (Administered Orally, Once Daily) for 6 Days in Healthy Male and Female Subjects", 
        "overall_contact": {
            "email": "clintriage.rdg@boehringer-ingelheim.com", 
            "last_name": "Boehringer Ingelheim Call Center", 
            "phone": "1-800-243-0127"
        }, 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of subjects with drug related adverse events", 
                "safety_issue": "No", 
                "time_frame": "17 days"
            }, 
            {
                "measure": "Change in minimum erythema dose (MED) at each wavelength tested, before and during treatment. The change will be quantified by the phototoxic index at 24 hrs (delayed erythema) derived by dividing the baseline MED by that during treatment", 
                "safety_issue": "Yes", 
                "time_frame": "7 days"
            }, 
            {
                "measure": "Percentage of subjects with drug related adverse events", 
                "safety_issue": "No", 
                "time_frame": "17 days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02114671"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Degree of phototoxic effects by phototoxic index", 
            "safety_issue": "Yes", 
            "time_frame": "7 days"
        }, 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}